Share Capital (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended					9 Months Ended	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jan. 31, 2022	Mar. 31, 2018	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Dec. 31, 2018	Sep. 30, 2022
Share Capital [Line Items]
Warrants outstanding to purchase common stock					1,828,854					1,828,854		3,103,864
Warrants exercise description										The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company.
Common Shares [Member]
Share Capital [Line Items]
Shares issued					855,685			9,098,362	258,986
Pre-funded warrants exercised					425,004					1,275,010
Common stock issued upon conversion of pre-funded warrants					425,000	425,000	425,000			1,275,000
Conversion of shares		1,016,000							1,016,000		1,852,000
March 2021
Share Capital [Line Items]
Warrants issued price per pre funded warrant					$ 18.4999					$ 18.4999
Warrants exercise price per common share					0.0001					0.0001
October 2021
Share Capital [Line Items]
Warrants issued price per pre funded warrant					29.4999					29.4999
Warrants exercise price per common share					0.0001					0.0001
June 2022
Share Capital [Line Items]
Warrants issued price per pre funded warrant					30.4999					30.4999
Warrants exercise price per common share					$ 0.0001					$ 0.0001
Jefferies L L C And Stifel Nicolaus Company Incorporated | At Market Equity Offering
Share Capital [Line Items]
Sale proceeds of common shares										$ 29,508
Jefferies L L C And Stifel Nicolaus Company Incorporated | At Market Equity Offering | Maximum [Member]
Share Capital [Line Items]
Gross proceeds from issuable of common stock										$ 250,000
Jefferies L L C And Stifel Nicolaus Company Incorporated | At Market Equity Offering | Common Shares [Member]
Share Capital [Line Items]
Shares issued										855,685
Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Shares issued	9,098,362
Shares price	$ 30.5							$ 30.5
Warrants outstanding to purchase common stock	327,868							327,868
Warrants issued price per pre funded warrant	$ 30.4999							$ 30.4999
Sale proceeds of common shares	$ 269,890
Warrants exercise price per common share	$ 0.0001							$ 0.0001
Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Over-Allotment Option [Member]
Share Capital [Line Items]
Shares issued	1,229,508
Neurocrine Biosciences [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares issued			258,986
Sale proceeds of common shares			$ 8,250
Aggregate purchase price per share			$ 31.855
Premium			$ 374
Series 1 Preferred Shares
Share Capital [Line Items]
Conversion of shares		1,016,000									1,852,000
BVF Partners L.P [Member] | Exchange Agreement [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares cancelled				2,868,000
BVF Partners L.P [Member] | Exchange Agreement [Member] | Series 1 Preferred Shares
Share Capital [Line Items]
Shares issued				2,868,000
Preferred shares convertible into common shares				one-for-one